CVR 32834825Public limited company (A/S)Fremstilling af farmaceutiske råvarer (211000)H E Bluhmes Vej 63, 6700 EsbjergFounded 4 Mar 2010
Compare withsimilar companiesanother companyits industry
ZPD A/S
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: ZPD A/S, https://dandex.ai/company/32834825/zpd. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about ZPD A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexEmployees
54
CVR, Aug 2026
+8 (+17.4%) over 12 months
Gross profit
52.7M
DKK, annual report 2025
+6.9% on 2024
Result
+10.2M
DKK, annual report 2025
Equity
217.6M
DKK, annual report 2025
Zeria Pharmaceutical Co. Ltd.Party outside CVR, Japan, 100% of capital and votes
Operating company
Dandex estimate: 54 employees registered in 2026Frank Mareksince 1 Sep 2013
Hiroyuki Shinyasince 1 Jan 2022
Kristian Jul Højlandsince 1 Oct 2026
and 1 moreOwners of 5% or more. CVR registers shares in bands, not exact figures.
Party outside CVR, Japan100% of capital and votessince 21 Aug 2013
1 Danish company.
SubsidiaryCVR 44407736100% of capital and votes
Danish companies held at 5% or more, from the CVR owner register (ejerregister), and their holdings one level down. Foreign holdings are not in CVR. Subsidiary (datterselskab): 50% or more of the votes, a Dandex estimate; in the 50% band a joint venture is not ruled out.
Aug 2026, monthly: 54 employees, 48 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 | Feb 2016 | Mar 2016 | Apr 2016 | May 2016 | Jun 2016 | Jul 2016 | Aug 2016 | Sep 2016 | Oct 2016 | Nov 2016 | Dec 2016 | Jan 2017 | Feb 2017 | Mar 2017 | Apr 2017 | May 2017 | Jun 2017 | Jul 2017 | Aug 2017 | Sep 2017 | Oct 2017 | Nov 2017 | Dec 2017 | Jan 2018 | Feb 2018 | Mar 2018 | Apr 2018 | May 2018 | Jun 2018 | Jul 2018 | Aug 2018 | Sep 2018 | Oct 2018 | Nov 2018 | Dec 2018 | Jan 2019 | Feb 2019 | Mar 2019 | Apr 2019 | May 2019 | Jun 2019 | Jul 2019 | Aug 2019 | Sep 2019 | Oct 2019 | Nov 2019 | Dec 2019 | Jan 2020 | Feb 2020 | Mar 2020 | Apr 2020 | May 2020 | Jun 2020 | Jul 2020 | Aug 2020 | Sep 2020 | Oct 2020 | Nov 2020 | Dec 2020 | Jan 2021 | Feb 2021 | Mar 2021 | Apr 2021 | May 2021 | Jun 2021 | Jul 2021 | Aug 2021 | Sep 2021 | Oct 2021 | Nov 2021 | Dec 2021 | Jan 2022 | Feb 2022 | Mar 2022 | Apr 2022 | May 2022 | Jun 2022 | Jul 2022 | Aug 2022 | Sep 2022 | Oct 2022 | Nov 2022 | Dec 2022 | Jan 2023 | Feb 2023 | Mar 2023 | Apr 2023 | May 2023 | Jun 2023 | Jul 2023 | Aug 2023 | Sep 2023 | Oct 2023 | Nov 2023 | Dec 2023 | Jan 2024 | Feb 2024 | Mar 2024 | Apr 2024 | May 2024 | Jun 2024 | Jul 2024 | Aug 2024 | Sep 2024 | Oct 2024 | Nov 2024 | Dec 2024 | Jan 2025 | Feb 2025 | Mar 2025 | Apr 2025 | May 2025 | Jun 2025 | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 | May 2026 | Jun 2026 | Jul 2026 | Aug 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | No count | 24 | 29 | 27 | 28 | 29 | 28 | 27 | 27 | 28 | 29 | 30 | 30 | 29 | 30 | 28 | 28 | 29 | 28 | 30 | 33 | 33 | 31 | 31 | 35 | 35 | 33 | 36 | 36 | 35 | 39 | 37 | 37 | 39 | 40 | 37 | 36 | 38 | 33 | 38 | 35 | 35 | 40 | 42 | 35 | 37 | 37 | 38 | 36 | 34 | 35 | 34 | 35 | 34 | 37 | 36 | 37 | 38 | 37 | 37 | 37 | 37 | 37 | 37 | 36 | 37 | 36 | 35 | 35 | 33 | 34 | 35 | 34 | 33 | 32 | 33 | 33 | 34 | 32 | 32 | 32 | 32 | 31 | 32 | 33 | 34 | 34 | 34 | 33 | 34 | 33 | 33 | 34 | 34 | 34 | 33 | 33 | 35 | 35 | 37 | 36 | 38 | 38 | 38 | 37 | 37 | 39 | 39 | 39 | 39 | 40 | 41 | 40 | 43 | 39 | 39 | 38 | 38 | 40 | 40 | 41 | 43 | 46 | 45 | 45 | 52 | 48 | 48 | 48 | 52 | 49 | 45 | 46 | 48 | 48 | 45 | 46 | 49 | 50 | 51 | 53 | 52 | 54 | 54 | 54 |
| FTE | 1 | 22 | 24 | 27 | 25 | 25 | 25 | 24 | 24 | 26 | 26 | 22 | 25 | 26 | 28 | 27 | 25 | 26 | 26 | 26 | 27 | 30 | 29 | 24 | 29 | 30 | 31 | 32 | 30 | 31 | 31 | 32 | 28 | 34 | 33 | 26 | 31 | 32 | 31 | 31 | 29 | 32 | 32 | 30 | 32 | 32 | 34 | 26 | 32 | 31 | 33 | 32 | 29 | 32 | 33 | 34 | 28 | 34 | 33 | 27 | 31 | 34 | 34 | 36 | 33 | 33 | 34 | 33 | 31 | 31 | 33 | 27 | 33 | 32 | 30 | 32 | 30 | 32 | 30 | 30 | 30 | 29 | 30 | 24 | 29 | 32 | 33 | 33 | 28 | 32 | 33 | 32 | 30 | 32 | 32 | 25 | 30 | 34 | 35 | 35 | 32 | 34 | 34 | 34 | 35 | 35 | 37 | 29 | 33 | 36 | 36 | 36 | 35 | 37 | 37 | 36 | 36 | 37 | 41 | 31 | 37 | 40 | 40 | 42 | 41 | 43 | 44 | 44 | 45 | 44 | 44 | 37 | 42 | 44 | 44 | 44 | 45 | 46 | 47 | 50 | 52 | 50 | 54 | 39 | 48 |
| Series | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group. CVR changed its monthly method in Oct 2019: a step there need not be real.
Source: CVR, latest Aug 2026, published 21 Oct 2026.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2025, DKK: Gross profit 52.7M, Operating profit 10.7M, Result for the year 10.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2025, DKK: Total assets 236.1M, Equity 217.6M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit | 35,200 | 37,256 | 43,788 | 49,315 | 52,704 |
| Operating profit | +9,819 | +9,641 | +12,925 | +13,260 | +10,657 |
| Result for the year | +6,963 | +7,067 | +11,824 | +12,864 | +10,220 |
| Equity | 178,166 | 185,232 | 197,056 | 208,920 | 217,641 |
| Total assets | 189,620 | 197,014 | 209,257 | 221,038 | 236,052 |
| Employees (average) | 35 | 35 | 39 | 42 | 48 |
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingNot read from the announcement | None | None | None | 1,000,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
The company's own figures, in DKK, from the annual reports filed in XBRL.
| DKK thousands | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Gross profit growth (vækst i bruttofortjeneste) | -1% | 5.8% | 17.5% | 12.6% | 6.9% |
| EBITDA | 12,999 | 12,979 | 16,234 | 16,875 | 14,936 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Employee growth (vækst i antal ansatte) | 0% | 0% | 11.4% | 7.7% | 14.3% |
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | 6,325 | 5,130 | 5,563 | 5,184 | 22,995 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 22 Nov 2026.
30 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 32834825 ZPD A/S (fortsættende), der tillige driver virksomhed under navnene BIOFAC ESBJERG A/S, ZERIA DENMARK A/S, ZERIA PHARMA DENMARK A/S, ZERIA PHARMACEUTICAL DENMARK A/S, ZP DENMARK A/S og CVR-nummer: 44407736 JoinHealth ApS (ophørende).
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 32834825 ZPD A/S og CVR-nummer: 44407736 JoinHealth ApS må antages at være tilstrækkeligt sikrede efter fusionen.
Bestyrelse:
Fratrådte:
Kenichi Suzuki, (formand), den 01.04.2023.
Tiltrådte:
Masakazu Sakurai, (formand), den 01.04.2023.
Bestyrelse:
Fratrådte:
Ken Motegi, (formand), den 12.07.2021.
Tiltrådte:
Kenichi Suzuki, (formand), den 12.07.2021.
Bestyrelse:
Fratrådte:
Yoshihiro Hiraga, (formand), den 22.04.2021.
Tiltrådte:
Ken Motegi, (formand), den 22.04.2021.
Bestyrelse:
Fratrådte:
Hiroki Kato, (formand), den 08.02.2019.
Tiltrådte:
Yoshihiro Hiraga, (formand), den 08.02.2019.
Bestyrelse:
Fratrådte:
Makoto Kishimoto (formand), den 28.05.2018.
Tiltrådte:
Hiroki Kato (formand), den 28.05.2018.
Bestyrelse:
Fratrådte:
Hiroyasu Nishioka, den 01.01.2017, Junkichi Izumi, den 01.01.2017, Keiji Ishiyama, den 01.01.2017.
Tiltrådte:
Frank Marek, den 01.01.2017, Katsuyuki Ishii, den 01.01.2017.
Direktion:
Fratrådte:
Frank Marek, den 01.01.2017, Hiroyasu Nishioka (adm. dir), den 01.01.2017.
Tiltrådte:
Frank Marek (adm. dir), den 01.01.2017, Ryu Nakao, den 01.08.2016.
CVR-nummer:
32834825.
NAVN:
ZPD A/S.
Adresse: H E Bluhmes Vej 63, 6700 Esbjerg.
Kommune: Esbjerg.
Vedtægter ændret:
14.01.2015.
Bestyrelse:
Udtrådt af bestyrelsen:
Shigeya Furuhata, den 24.03.2014, Elio Ramon Loo, den 24.03.2014.
Indtrådt i bestyrelsen:
Makoto Kishimoto (formand), den 24.03.2014.
Direktion:
Tiltrådt som adm. dir: Hiroyasu Nishioka, den 24.03.2014.
Udtrådt af direktionen:
Elio Ramon Loo, den 24.03.2014.
Bestyrelse:
Indtrådt i bestyrelsen:
Keiji Ishiyama, den 09.07.2013, Hiroyasu Nishioka, den 09.07.2013.
Vedtægter ændret:
25.03.2013.
Nyt navn:
ZPD A/S.
Nye binavne:
BIOFAC ESBJERG A/S, ZERIA DENMARK A/S, ZERIA PHARMA DENMARK A/S, ZERIA PHARMACEUTICAL DENMARK A/S, ZP DENMARK A/S.
Bestyrelse:
Udtrådt af bestyrelsen:
Peter Rørvig, den 22.08.2012.
Direktion:
Udtrådt af direktionen:
Helle Rørvig, den 22.08.2012.
Bestyrelse:
Udtrådt af bestyrelsen:
Nobuhito Hashimoto, den 28.06.2012.
Indtrådt i bestyrelsen:
Akihisa Ono, den 28.06.2012.
Ny adresse:
H E Bluhmes Vej 63, 6700 Esbjerg.
Ny kommune:
Esbjerg.
Vedrørende den under 18.04.2011 registrerede ændring for CVR-nr. 32834825 BIOFAC ESBJERG A/S meddeles, at følgende person(er) ved en fejl blev registreret som indtrådt i bestyrelsen: Nobuhito Hashimoto den 18. april 2011 han er rettelig indtrådt den 1. april 2011 og Mitsuhiro Tago er rettelig fratrådt den 1. april 2011.
Bestyrelse:
Udtrådt af bestyrelsen:
Mitsuhiro Tago, den 18.04.2011.
Indtrådt i bestyrelsen:
Nobuhito Hashimoto, den 18.04.2011.
Vedtægter ændret:
04.11.2010.
Direktion:
Tiltrådt som adm. dir: Elio Ramon Loo.
Ny adresse:
Englandsvej 350, 2770 Kastrup.
Ny kommune:
Tårnby.
Vedtægter ændret:
16.09.2010.
Ny adresse:
H E Bluhmes Vej 63, 6700 Esbjerg.
Ny kommune:
Esbjerg.
Bestyrelse:
Udtrådt af bestyrelsen:
Svend Blankholm, den 16.09.2010, Niels Ulrik Heine, den 16.09.2010, Helle Rørvig, den 16.09.2010.
Indtrådt i bestyrelsen:
Shigeya Furuhata (formand), den 16.09.2010, Elio Ramon Loo, den 16.09.2010, Mitsuhiro Tago, den 16.09.2010.
Selskabet tegnes af to bestyrelsesmedlemmer i forening, af et bestyrelsesmedlem i forening med en direktør eller af den samlede bestyrelse.
Revision:
Udtrådt af revisionen:
CVR-NR. 16994294 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, den 16.09.2010.
Indtrådt i revisionen:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Borups Allé 177, 2400 København NV, den 16.09.2010.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.07.2010 - 31.12.2011.
Direktion:
Udtrådt af direktionen:
Peter Rørvig, den 16.09.2010.
Indtrådt i direktionen:
Elio Ramon Loo, den 16.09.2010, Civiling Robert Villum Nielsen, den 16.09.2010, Hiroyasu Nishioka, den 16.09.2010.
Selskabet er stiftet ved spaltning, den 04.03.2010 Selskabets aktiver og gæld er overdraget fra CVR-NR. 62550511 BIOFAC A/S.
Seneste vedtægtsdato:
04.03.2010.
Kapital:
kr. 1.000.000,00.
Indbetalingsmåde:
spaltning kr. 1.000.000,00 til kurs 3.640,83.
Bestyrelse:
Direktør Svend Blankholm, 2950 Vedbæk, den 04.03.2010, Advokat Niels Ulrik Heine, 2840 Holte, den 04.03.2010, Helle Rørvig, 2840 Holte, den 04.03.2010, Direktør Peter Rørvig, 2840 Holte, den 04.03.2010.
Direktion:
Direktør Peter Rørvig, 2840 Holte, den 04.03.2010.
Selskabet tegnes af en direktør eller af to bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 16994294 PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSAKTIESELSKAB, Strandvejen 44, 2900 Hellerup, den 04.03.2010.
Første regnskabsår:
01.07.2009 - 30.06.2010.
Regnskabsår:
01.07 - 30.06.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for ZPD A/S:
Have Pro? Sign in.
P-number 1015956476H E Bluhmes Vej 63, 6700 Esbjerg
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.
No other current company drawn.